tbuckley/cabot-search huggingface dataset:
IL-6-elafin genetically modified macrophages as a lung immunotherapeutic strategy against Pseudomonas aeruginosa infections
Authors: Saadé Kheir, Bérengère Villeret, Ignacio Garcia-Verdugo, Jean-Michel Sallenave
Journal: Molecular Therapy (2021)

Pseudomonas aeruginosa (P.a) infections are a major public health issue in ventilator-associated pneumoniae, cystic fibrosis, and chronic obstructive pulmonary disease exacerbations. P.a is multidrug resistant, and there is an urgent need to develop new therapeutic approaches. Here, we evaluated the effect of direct pulmonary transplantation of gene-modified (elafin and interleukin [IL]-6) syngeneic macrophages in a mouse model of acute P.a infection. Wild-type (WT) or Elafin-transgenic (eTg) alveolar macrophages (AMs) or bone marrow-derived macrophages (BMDMs) were recovered from bronchoalveolar lavage or generated from WT or eTg mouse bone marrow. Cells were modified with adenovirus IL-6 (Ad-IL-6), characterized in vitro, and transferred by oropharyngeal instillation in the lungs of naive mice. The protective effect was assessed during P.a acute infection (survival studies, mechanistic studies of the inflammatory response). We show that a single bolus of genetically modified syngeneic AMs or BMDMs provided protection in our P.a-induced model. Mechanistically, Elafin-modified AMs had an IL-6-IL-10-IL-4R-IL-22-antimicrobial molecular signature that, in synergy with IL-6, enhanced epithelial cell proliferation and tissue repair in the alveolar unit. We believe that this innovative cell therapy strategy could be of value in acute bacterial infections in the lung.
25587 The experience of COVID-19 and its impact on management of hidradenitis suppurativa
Authors: Gabrielle Benesh, Tyler M. Andriano, Kayla M. Babbush, Steven R. Cohen
Journal: Journal of the American Academy of Dermatology (2021)

The COVID-19 pandemic altered health care delivery for various dermatologic conditions; however, there is a paucity of data about hidradenitis suppurativa (HS). We investigated the COVID-19 experience of patients with HS during the pandemic. We performed retrospective chart reviews and telephone surveys of 90 patients seen at the Einstein/Montefiore HS Center between May and August 2020. Participants were mostly female (73.3%) with a mean age of 36.7 ± 13.7 years. The mean HS-Physician Global Assessment (HS-PGA) score, a marker of disease severity, was 2.48 ± 1.32. Eight (8.89%) patients self-reported COVID-19 positive tests with a mean HS-PGA of 3.00 ± 1.19; 2 (25.0%) were hospitalized; and, 1 (12.5%) required mechanical ventilation. Reported symptoms included fever, cough, dyspnea, myalgias, anosmia, and ageusia. There was no recorded mortality. Rates of COVID-19 were similar among those treated with biologics compared to the remainder of the cohort (10.3% vs 6.3%; P = .51). It is of considerable interest that 64.4% of this cohort was on therapy with biologic agents (infliximab, 93.1%; adalimumab, 6.90%). Thirty-six (40.0%) reported difficulty accessing care during the pandemic, including 5 testing positive for COVID-19. Reported challenges consisted of acute flares (22.2%), interrupted treatment (s) (41.7%) [eg, biologic infusions, intralesional corticosteroid injections, drainage of abscesses] and overall worsening of HS (11.1%). This pilot study suggests the COVID-19 pandemic has had a substantial impact on HS. More than a third of the cohort identified major obstacles in disease management. Our study of COVID-19 occurrence associated with HS underscores the critical importance of health care access in the care of these patients.
Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study
Authors: Qing Zhou, Chong-Rui Xu, Ying Cheng, Yun-Peng Liu, Gong-Yan Chen, Jiu-Wei Cui, Nong Yang, Yong Song, Xiao-Ling Li, Shun Lu, Jian-Ying Zhou, Zhi-Yong Ma, Shi-Ying Yu, Cheng Huang, Yong-Qian Shu, Zhen Wang, Jin-Ji Yang, Hai-Yan Tu, Wen-Zhao Zhong, Yi-Long Wu
Journal: Cancer Cell (2021)
前立腺癌のEAUガイドライン。パート1:臨床的限局性疾患のスクリーニング,診断および治療
Authors: A Heidenreich, J Bellmunt, M Bolla, S Joniau, M Mason, V Matveev, N Mottet, Schmid H.-P., T Van Der Kwast, T Wiegel, F Zattoni
Journal: European Urology (2011)
次世代薬物溶出ステントであるビオリムス溶出ステント,エベロリムス溶出ステント,ゾタロリムス溶出ステントの有効性の比較
Authors: Tokuda Takahiro, Tsukahara Reiko, Muramatsu Toshiya, Itoh Yoshiaki, Sakai Tsuyoshi, Ishimori Hiroshi, Hirano Keisuke, Nakano Masatsugu, Yamawaki Masahiro, Katoh Tamon, Kobayashi Norihiro, Takimura Hideyuki, Sakamoto Yasunari, Takama Takurou
Journal: Circulation (2013)
Long-Term Exposure to Road Traffic Noise and Air Pollution, and Incident Atrial Fibrillation in the Danish Nurse Cohort
Authors: Zorana J. Andersen, Johannah Cramer, Jeanette T. Jørgensen, Christian Dehlendorff, Heresh Amini, Amar Mehta, Tom Cole-Hunter, Laust H. Mortensen, Rudi Westendorp, Rina So, Shuo Li, Barbara Hoffmann, Steffen Loft, Elvira V. Bräuner, Matthias Ketzel, Ole Hertel, Jørgen Brandt, Steen Solvang Jensen, Jesper H. Christensen, Camilla Geels, Lise M. Frohn, Claus Backalarz, Mette K. Simonsen, Youn-Hee Lim
Journal: Environmental Health Perspectives (2021)

BACKGROUND: Associations between long-term exposure to air pollution and road traffic noise have been established for ischemic heart disease, but findings have been mixed for atrial fibrillation (AF). OBJECTIVES:The goal of the study was to examine associations of long-term exposure to road traffic noise and air pollution with AF.METHODS: Time-varying Cox regression models were used to estimate associations of 1-, 3-, and 23-y mean road traffic noise and air pollution exposures with AF incidence in 23,528 women enrolled in the Danish Nurse Cohort (age >44 y at baseline in 1993 or 1999).AF diagnoses were ascertained via the Danish National Patient Register.Annual mean weighted 24-h average road traffic noise levels (L den ) at the nurses' residences, since 1970, were estimated using the Nord2000 model, and annual mean levels of particulate matter with a diameter <2:5 lm (PM 2:5 ) and nitrogen dioxide (NO 2 ) were estimated using the DEHM/UBM/AirGIS model.RESULTS: Of 23,528 nurses with no prior AF diagnosis at the cohort baseline, 1,522 developed AF during follow-up.In a fully adjusted model (including PM 2:5 ), the estimated risk of AF was 18% higher [hazard ratio (HR); 95% confidence interval (CI): 1.18; 1.02, 1.36] in nurses with residential 3-y mean L den levels >58 dB vs. <48 dB, with similar findings for 1-y mean exposures.A 3:9-lg=m 3 increase in 3-y mean PM 2:5 was associated with incident AF before and after adjustment for concurrent exposure to road traffic noise (HR 1.09; 95% CI: 1.00, 1.20 and 1.08; 95% CI: 0.97, 1.19, respectively).Associations with 1-y mean PM 2:5 exposures were positive but closer to the null and not significant.Associations with NO 2 were null for all time periods before and after adjustment for road traffic noise and inverse when adjusted for concurrent PM 2:5 .CONCLUSION: Our analysis of prospective data from a cohort of Danish female nurses followed for up to 14 y provided suggestive evidence of independent associations between incident AF and 1-and 3-y exposures to road traffic noise and PM 2:5 .
Tinea Facei From <i>Trichophyton benhamiae</i> From a Pet Guinea Pig
Authors: Helena Iznardo, Cristina Garcia-Melendo, Carla Berengua
Journal: JAMA Dermatology (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
SO-3 Treatment sequences and prognostic factors in metastatic pancreatic ductal adenocarcinoma: Univariate and multivariate analyses of a real-world study in Europe
Authors: J. Taieb, P. Hammel, M. Reni, D. Palmer, J. Bridgewater, A. Cubillo, G. Prager, S. Bayle, F. Hédouin-Biville, Z. Teng, T. Seufferlein, T. Macarulla
Journal: Annals of Oncology (2021)
Environmental enteric dysfunction induces regulatory T cells that inhibit local CD4+ T cell responses and impair oral vaccine efficacy
Authors: Amrita Bhattacharjee, Ansen H.P. Burr, Abigail E. Overacre-Delgoffe, Justin T. Tometich, Deyi Yang, Brydie R. Huckestein, Jonathan L. Linehan, Sean P. Spencer, Jason A. Hall, Oliver J. Harrison, Denise Morais da Fonseca, Elizabeth B. Norton, Yasmine Belkaid, Timothy W. Hand
Journal: Immunity (2021)
MDM2小分子拮抗薬RG7112は,臨床前癌モデルにおいてp53シグナル伝達を活性化し,ヒト腫瘍を退行させる
Authors: Tovar Christian, Graves Bradford, Packman Kathryn, Filipovic Zoran, Xia Brian Higgins Mingxuan, Tardell Christine, Garrido Rosario, Lee Edmund, Kolinsky Kenneth, TO Kwong-Him, Linn Michael, Podlaski Frank, Wovkulich Peter, VU Binh, T Vassilev Lyubomir
Journal: Cancer Research (2013)
Randomised controlled trial of a prognostic assessment and management pathway to reduce the length of hospital stay in normotensive patients with acute pulmonary embolism
Authors: David Jiménez, Carmen Rodríguez, Francisco León, Luis Jara-Palomares, Raquel López-Reyes, Pedro Ruiz-Artacho, Teresa Elías, Remedios Otero, Alberto García-Ortega, Agustina Rivas-Guerrero, Jaime Abelaira, Sonia Jiménez, Alfonso Muriel, Raquel Morillo, Deisy Barrios, Raphael Le Mao, Roger D. Yusen, Behnood Bikdeli, Manuel Monreal, José Luis Lobo
Journal: European Respiratory Journal (2021)

Background The length of hospital stay (LOS) for acute pulmonary embolism (PE) varies considerably. Whether the upfront use of a PE prognostic assessment and management pathway is effective in reducing the LOS remains unknown. Methods We conducted a randomised controlled trial of adults hospitalised for acute PE: patients were assigned either to a prognostic assessment and management pathway involving risk stratification followed by predefined criteria for mobilisation and discharge (intervention group) or to usual care (control group). The primary end-point was LOS. The secondary end-points were the cost of prognostic tests and of hospitalisation, and 30-day clinical outcomes. Results Of 500 patients who underwent randomisation, 498 were included in the modified intention-to-treat analysis. The median LOS was 4.0 days (interquartile range (IQR) 3.7–4.2 days) in the intervention group and 6.1 days (IQR 5.7–6.5 days) in the control group (p&lt;0.001). The mean total cost of prognostic tests was EUR 174.76 in the intervention group, compared with EUR 233.12 in the control group (mean difference EUR −58.37, 95% CI EUR −84.34­ to −32.40). The mean total hospitalisation cost per patient was EUR 2085.66 in the intervention group, compared with EUR 3232.97 in the control group (mean difference EUR −1147.31, 95% CI EUR −1414.97­ to −879.65). No significant differences were observed in 30-day readmission (4.0% versus 4.8%), all-cause mortality (2.4% versus 2.0%) or PE-related mortality (0.8% versus 1.2%) rates. Conclusions The use of a prognostic assessment and management pathway was effective in reducing the LOS for acute PE.
TCT-392 Application and Outcomes of a Hybrid Approach to Chronic Total Occlusion Percutaneous Coronary Intervention in a Contemporary Multicenter US Registry
Authors: Georgios Christopoulos, Dimitri Karmpaliotis, Khaldoon Alaswad, Robert Yeh, Farouc Jaffer, R. Michael Wyman, William Lombardi, Rohan V. Menon, J. Aaron Grantham, David Kandzari, Nicholas Lembo, Jeffrey W. Moses, Ajay J. Kirtane, Manish Parikh, Philip Green, Matthew T. Finn, Santiago Garcia, Anthony H. Doing, Mitul Patel, John Bahadorani, Muhammad Nauman J. Tarar, Georgios E. Christakopoulos, Craig Thompson, Subhash Banerjee, Emmanouil Brilakis
Journal: Journal of the American College of Cardiology (2015)
The New Worldwide Definition of Metabolic Syndrome Is Not a Better Diagnostic Predictor of Cardiovascular Disease in Japanese Diabetic Patients Than the Existing Definitions
Authors: Hirohito Sone, Sachiko Tanaka, Shun Ishibashi, Yoshimitsu Yamasaki, Shinichi Oikawa, Hideki Ito, Yasushi Saito, Yasuo Ohashi, Yasuo Akanuma, Nobuhiro Yamada
Journal: Diabetes Care (2006)

We previously reported (1) the limited clinical significance for Japanese diabetic patients of the widely used World Health Organization (WHO) (2) and National Cholesterol Education Program (NCEP) (3) definitions of metabolic syndrome and suggested that an international definition of metabolic syndrome that was applicable regardless of ethnicity was necessary (1).

Recently, the International Diabetes Federation published a long-awaited new worldwide definition of metabolic syndrome (4) that is intended to be applicable to various ethnic groups. The new definition is similar to the NCEP definition (3) but has several important differences. Notably, most components of the new definition now include subjects who are receiving specific treatments for the abnormalities that comprise metabolic syndrome. Also, central obesity (defined by waist circumference with ethnic modification in its thresholds) has become a mandatory component in the new definition. In this report, we evaluated the predictive power of the new international definition for cardiovascular disease (CVD), as compared with that of previous definitions, in Japanese diabetic patients.

The Japan Diabetes Complications Study (JDCS) has been described in detail elsewhere (1, 5). The same dataset was used for evaluation so that the new definition of metabolic syndrome could be directly compared with the WHO and NCEP definitions (1–4). A total of 1,424 Japanese patients (771 men and 653 women, age 58.4 ± 7.4 years [means ± SD]) with previously diagnosed type 2 diabetes but without known CVD were …
A bovine lactoferricin-lactoferrampin-encoding <i>Lactobacillus reuteri</i> CO21 regulates the intestinal mucosal immunity and enhances the protection of piglets against enterotoxigenic <i>Escherichia coli</i> K88 challenge
Authors: Weichun Xie, Liying Song, Xueying Wang, Yigang Xu, Zengsu Liu, Dongfang Zhao, Shubo Wang, Xiaolong Fan, Zhaorui Wang, Chong Gao, Xiaona Wang, Li Wang, Xinyuan Qiao, Han Zhou, Wen Cui, Yanping Jiang, Yijing Li, Lijie Tang
Journal: Gut Microbes (2021)

Enterotoxigenic Escherichia coli (ETEC) is an important cause of diarrhea in human and animal. To determine the mechanism of a bovine lactoferricin-lactoferrampin (LFCA)-encoding Lactobacillus reuteri CO21 (LR-LFCA) to enhance the intestinal mucosal immunity, we used a newborn piglet intestine model to study the intestinal response to ETEC. Pigs were chosen due to the anatomical similarity between the porcine and the human intestine.4-day-old piglets were orally administered with LR-LFCA, LR-con (L. reuteri CO21 transformed with pPG612 plasmid) or phosphate buffered saline (PBS) for three consecutive days, within 21 days after these treatments, we found that LR-LFCA can colonize the intestines of piglets, improve the growth performance, enhance immune response and is beneficial for intestinal health of piglets by improving intestinal barrier function and modulating the composition of gut microbiota. Twenty-one days after, piglets were infected with ETEC K88 for 5 days, we found that oral administration of LR-LFCA to neonatal piglets attenuated ETEC-induced the weight loss of piglets and diarrhea incidence. LR-LFCA decreased the production of inflammatory factors and oxidative stress in intestinal mucosa of ETEC-infected piglets. Additionally, LR-LFCA increased the expression of tight junction proteins in the ileum of ETEC-infected piglets. Using LPS-induced porcine intestinal epithelial cells (IPEC-J2) in vitro, we demonstrated that LR-LFCA-mediated increases in the tight junction proteins might depend on the MLCK pathway; LR-LFCA might increase the anti-inflammatory ability by inhibiting the NF-κB pathway. We also found that LR-LFCA may enhance the antioxidant capacity of piglets by activating the Nrf2/HO-1 pathway. This study demonstrates that LR-LFCA is effective at maintaining intestinal epithelial integrity and host homeostasis as well as at repairing intestinal damage after ETEC infection and is thus a promising alternative therapeutic method for intestinal inflammation.
Long-term (7-year) Clinical Outcomes after Biodegradable Polymer-based Biomatrix Biolimus-eluting Stent Implantation
Authors: Ohya Masanobu, Kadota Kazushige, Hyodo Yusuke, Otsuru Suguru, Hasegawa Daiji, Habara Seiji, Tada Takeshi, Tanaka Hiroyuki, Fuku Yasushi, Goto Tsuyoshi, Mitsudo Kazuaki
Journal: Circulation (2016)
A Mendelian randomization study found causal linkage between telomere attrition and chronic kidney disease
Authors: Sehoon Park, Soojin Lee, Yaerim Kim, Semin Cho, Kwangsoo Kim, Yong Chul Kim, Seung Seok Han, Hajeong Lee, Jung Pyo Lee, Kwon Wook Joo, Chun Soo Lim, Yon Su Kim, Dong Ki Kim
Journal: Kidney International (2021)
Antiphospholipid antibodies and COVID-19 thrombotic vasculopathy: one swallow does not make a summer
Authors: Pier Luigi Meroni, Maria Orietta Borghi
Journal: Annals of the Rheumatic Diseases (2021)

The high morbidity and mortality of COVID-19 have been associated with the thrombotic microangiopathy described in the patients in addition to the increased prevalence of thrombosis affecting medium/large arterial and venous vessels.1 2 Initial reports demonstrating prolonged activated partial thromboplastin times (aPTT) and positivity for antiphospholipid antibody (aPL) assays raised the issue of whether common pathogenic mechanisms were shared by the antiphospholipid antibody syndrome (APS) and COVID-19.3 4 In particular, the systemic thrombotic microangiopathy and the increased circulating levels of proinflammatory cytokines underlined the similarity between catastrophic APS (CAPS) and COVID-19.5 6 

The similarities between APS/CAPS and COVID-19 are even more complex and intriguing as summarised in table 1. A proinflammatory environment that includes the activation of the complement system has been reported in all these conditions, although at different degrees. The involvement of several cell types playing a role in the coagulation cascade, such as platelets, monocytes and neutrophils, has been described which is closely associated with the proinflammatory and prothrombotic phenotypes.7 8 In particular, an endothelial perturbation is generally thought to be a common denominator in these diseases and several authors described it with the term ‘endothelitis’ in the COVID-19.9–11 

View this table:

Table 1 
Pathogenic pathways reported in APS, CAPS and COVID-19



Both proinflammatory cytokine (eg, interleukin-6) and complement activation products (ie, C5a and C5b9) were thought to play a role in mediating the endothelitis together with a direct effect of SARS-CoV-2 on the endothelium.10–12 However, the SARS-CoV-2 endothelial tropism is still a matter of debate despite the presence of the entry molecule (ie, ACE2) on the endothelial surfaces.13 So, it is not surprising that additional potential mediators of endothelial perturbation have been suggested. In particular, aPL came into the limelight because of their well-known …
Rapid Increase in Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant — Mesa County, Colorado, April–June 2021
Authors: Rachel Herlihy, Wendy Bamberg, Alexis Burakoff, Nisha Alden, Rachel Severson, Eric Bush, Breanna Kawasaki, Brynn Berger, Elizabeth Austin, Meghan Shea, Eduardo Gabrieloff, Shannon Matzinger, April Burdorf, Janell Nichols, Kim Goode, Alana Cilwick, Chelsea Stacy, Erin Staples, Ginger Stringer
Journal: MMWR Morbidity and Mortality Weekly Report (2021)

On May 5, 2021, the Colorado Department of Public Health and Environment (CDPHE) identified the first five COVID-19 cases caused by the SARS-CoV-2 B.1.617.2 (Delta) variant in Mesa County in western Colorado (population 154,933, <3% of the state population). All five initial cases were associated with school settings. Through early June, Mesa County experienced a marked increase in the proportion of Delta variant cases identified through sequencing: the 7-day proportion of sequenced specimens identified as B.1.617.2 in Mesa County more than doubled, from 43% for the week ending May 1 to 88% for the week ending June 5. As of June 6, more than one half (51%) of sequenced B.1.617.2 specimens in Colorado were from Mesa County. CDPHE assessed data from surveillance, vaccination, laboratory, and hospital sources to describe the preliminary epidemiology of the Delta variant and calculate crude vaccine effectiveness (VE). Vaccination coverage in early May in Mesa County was lower (36% of eligible residents fully vaccinated) than that in the rest of the state (44%). Compared with that in all other Colorado counties, incidence, intensive care unit (ICU) admissions, and COVID-19 case fatality ratios were significantly higher in Mesa County during the analysis period, April 27-June 6, 2021. In addition, during the same time period, the proportion of COVID-19 cases in persons who were fully vaccinated (vaccine breakthrough cases) was significantly higher in Mesa County compared with that in all other Colorado counties. Estimated crude VE against reported symptomatic infection for a 2-week period ending June 5 was 78% (95% confidence interval [CI] = 71%-84%) for Mesa County and 89% (95% CI = 88%-91%) for other Colorado counties. Vaccination is a critical strategy for preventing infection, serious illness, and death from COVID-19. Enhanced mitigation strategies, including masking in indoor settings irrespective of vaccination status, should be considered in areas with substantial or high case rates.